TScan Therapeutics, Inc.
TCRX
$1.08
$0.032.86%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -22.98M | -35.71M | -36.95M | -34.13M | -35.81M |
| Total Depreciation and Amortization | 723.00K | 767.00K | 698.00K | 678.00K | 711.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.07M | 2.84M | 2.60M | 2.25M | 2.43M |
| Change in Net Operating Assets | -11.82M | -359.00K | 386.00K | -6.38M | 5.26M |
| Cash from Operations | -32.00M | -32.46M | -33.27M | -37.59M | -27.41M |
| Capital Expenditure | -171.00K | -1.43M | -1.28M | -1.53M | -888.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 15.00M | 34.00M | 49.72M | 15.06M | 28.18M |
| Cash from Investing | 14.83M | 32.58M | 48.44M | 13.53M | 27.29M |
| Total Debt Issued | -- | -- | -- | -- | 32.46M |
| Total Debt Repaid | -- | -- | -- | -- | -17.14M |
| Issuance of Common Stock | 73.00K | 0.00 | 191.00K | -- | 378.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | -75.00K | -525.00K | 30.00M |
| Cash from Financing | 73.00K | 0.00 | 116.00K | -525.00K | 45.69M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -17.10M | 112.00K | 15.29M | -24.58M | 45.57M |